Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Dent

Showing results (1-10 of 395) with videos related to

Pageof 40
Sort By:
Expert Opinion on Investigational Drugs|December 1, 2019
Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancerPaul Dent
Cancer Biology & Therapy|February 6, 2014
Not so WEE: targeting G₂/M to kill mesothelioma cellsPaul Dent
Cancer Biology & Therapy|March 13, 2014
New methods to control neuroblastoma growthPaul Dent
Cancer Biology & Therapy|August 27, 2013
HDACIs and the inhibition of invasive potentialPaul Dent
Cancer Biology & Therapy|August 27, 2013
The multi-hit hypothesis in basal-like breast cancerPaul Dent
Cancer Biology & Therapy|September 13, 2013
Arsenic in leukemia: a RSKy businessPaul Dent
Cancer Biology & Therapy|August 27, 2013
The flip side of doxorubicin: Inflammatory and tumor promoting cytokinesPaul Dent
Cancer Biology & Therapy|August 27, 2013
FADD the bad in head and neck cancerPaul Dent
Cancer Biology & Therapy|September 13, 2013
Multi-kinase modulation for colon cancer therapyPaul Dent
Cancer Biology & Therapy|September 13, 2013
ERK plays the baddie (again)Paul Dent
Pageof 40

Showing results (1-10 of 395) with videos related to

Sort By:
Pageof 40
Expert Opinion on Investigational Drugs|December 1, 2019
Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancerPaul Dent
Cancer Biology & Therapy|February 6, 2014
Not so WEE: targeting G₂/M to kill mesothelioma cellsPaul Dent
Cancer Biology & Therapy|March 13, 2014
New methods to control neuroblastoma growthPaul Dent
Cancer Biology & Therapy|August 27, 2013
HDACIs and the inhibition of invasive potentialPaul Dent
Cancer Biology & Therapy|August 27, 2013
The multi-hit hypothesis in basal-like breast cancerPaul Dent
Cancer Biology & Therapy|September 13, 2013
Arsenic in leukemia: a RSKy businessPaul Dent
Cancer Biology & Therapy|August 27, 2013
The flip side of doxorubicin: Inflammatory and tumor promoting cytokinesPaul Dent
Cancer Biology & Therapy|August 27, 2013
FADD the bad in head and neck cancerPaul Dent
Cancer Biology & Therapy|September 13, 2013
Multi-kinase modulation for colon cancer therapyPaul Dent
Cancer Biology & Therapy|September 13, 2013
ERK plays the baddie (again)Paul Dent
Pageof 40